^
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C3 – Early Trials
Clin Cancer Res - 6 days
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
neratinib
Sensitive: C3 – Early Trials
Clin Cancer Res - 6 days
SOX2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
Pharmacol Rep - 2 weeks
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + GZ17-6.02
Sensitive: D – Preclinical
Oncotarget - 2 weeks
PTEN Hypermethylation
Hormone Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
PTEN underexpression
Hormone Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
lapatinib
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
palbociclib
Resistant: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
everolimus
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor + palbociclib
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
BRCA1 mutation
Hormone Receptor Positive Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
CDK6 inhibitor + Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
CDK4 inhibitor + Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab + lapatinib
Resistant: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab
Resistant: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
lapatinib
Resistant: B - Late Trials
CCNE1 overexpression
Hormone Receptor Positive Breast Cancer
palbociclib
Resistant: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
PLK1-H
Hormone Receptor Positive Breast Cancer
palbociclib
Resistant: B - Late Trials
TP53 mutation
Hormone Receptor Positive Breast Cancer
capecitabine
Resistant: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
capecitabine
Sensitive: B - Late Trials
BRCA1 mutation
Hormone Receptor Positive Breast Cancer
ABT-888
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
palbociclib + abemaciclib
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: B - Late Trials
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
ABT-888
Sensitive: B - Late Trials
ER mutation
Hormone Receptor Positive Breast Cancer
exemestane
Resistant: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
exemestane
Resistant: B - Late Trials
FGFR1 amplification
Hormone Receptor Positive Breast Cancer
letrozole
Resistant: B - Late Trials
ER rs2234693
Hormone Receptor Positive Breast Cancer
exemestane
Sensitive: B - Late Trials
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
ER mutation
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: B - Late Trials
HR positive + HER-2 positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor + trastuzumab + lapatinib
Sensitive: B - Late Trials
BRCA1 mutation
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: B - Late Trials
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: B - Late Trials
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
abemaciclib
Resistant: C1 - Off-label
PIK3CA mutation + HR positive
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: C1 - Off-label
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive: C2 – Inclusion Criteria
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
HR positive
Hormone Receptor Positive Breast Cancer
enzalutamide
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
ribociclib
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C2 – Inclusion Criteria
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
FTO expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
BIN3 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
ER Y537S
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: C3 – Early Trials
PIK3R1 mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Resistant: C3 – Early Trials
CDK6 overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant: C3 – Early Trials
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
USH2A mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Sensitive: C3 – Early Trials
NEFH mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Sensitive: C3 – Early Trials
APC mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Resistant: C3 – Early Trials
PTCH1 mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Sensitive: C3 – Early Trials
PALB2 mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Resistant: C3 – Early Trials
NOS2 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
TK1-H
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Sensitive: C3 – Early Trials
HPGD underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Resistant: C3 – Early Trials
BRCA1 mutation
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Resistant: C3 – Early Trials
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Sensitive: C3 – Early Trials
CCNE1 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CDK2 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CCND1 amplification
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C2 – Inclusion Criteria
CCNE1-H
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
ER-L
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C2 – Inclusion Criteria
ER mutation
Estrogen Receptor Positive Breast Cancer
enobosarm
Sensitive: C3 – Early Trials